Mounjaro Weight Loss Jab Linked to Increased Adverse Reactions and Deaths in 2025
In 2025, the weight loss injection Mounjaro saw a significant rise in adverse reactions, with a 300 percent increase in reported cases compared to the previous year. According to data from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme, there were 40,245 reported reactions, including 6,755 classified as serious and 71 resulting in death. The most common side effects were gastrointestinal disorders, with 37,546 reports, 19 of which were fatal. The NHS lists nausea, diarrhea, and abdominal cramps as potential side effects. A notable case involved Karen Coe, who experienced severe reactions after her first injection, leading to hospitalization. The manufacturer, Eli Lilly and Company, emphasizes patient safety and encourages reporting adverse events. The MHRA has updated product information to include a risk of severe acute pancreatitis, a condition that can lead to serious complications. 
